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     SUMMARY     
HEART RATE VARIABILITY IN CHILDREN WITH SUPRAVENTRICULAR ARRHYTHMIAS 
Key words:   bisoprolol, heart rate variability, supraventricular arrhythmias.
Th e following reasearch was made upon 50 children, age between 7 and 18 years, with supraventricular arrhythmias: 
the fi rst group includes 30 children (average age 12,93±0,52 years) that have been administared bisoprolol with the 
average dose  1,25-2,5/mg/24 h and the second  group, (average dose 13,55±0,60 years) that received  placebo. 
Th e research results revealed that the arrhythmias has been associated with diff erent symptoms as cardiac pains (90%) 
and palpitation (88%). Th e action of bisoprolol on the parameters of heart rate variability has been established by 
the decreased value of the statistics and spectral indexes that show the activity of the sympathetic vegetative nervous 
system. Th e bisoprolol can be recommended to children with symptomatic supraventricular premature beats while 
being a cardioselective  drug with a high selectivity index (1:75).
     REZUMAT     
 VARIABILITATEA RITMULUI CARDIAC LA COPII CU ARITMII SUPRAVENTRICULARE
Cuvinte-cheie: bisoprolol, variabilitatea ritmului cardiac, aritmii supraventriculare.
Studiul a fost efectuat pe un lot de 50 de copii, cu vârsta cuprinsă între 7 și 18 ani, cu aritmii supraventriculare: lotul 
I, de bază a inclus 30 copii (vârsta medie 12,93±0,52 ani), cărora li s-a administrat bisoprolol în doza uzuală 1,25-2,5/
mg/24 ore, și lotul II, martor – 20 de copii, (vârsta medie 13,55±0,60 ani), care au primit placebo. 
Rezultatele studiului au relevat asocierea aritmiilor supraventriculare cu diverse simptome clinice cu predominarea 
durerilor precordiale (90%) și a palpitaţiilor (88%). Acţiunea bisoprololului asupra parametrilor variabilităţii ritmului 
cardiac s-a exprimat prin micșorarea indicilor statistici și spectrali caracteristici pentru activitatea sistemului nervos 
vegetativ simpatic. Bisoprololul poate fi  recomandat în schema de tratament la copii cu aritmii supraventriculare, fi ind 
un preparat cardioselectiv cu indicele de selectivitate înalt (1:75).
Introduction. 
Supraventricular arrythmias are common and patients 
are oft en symptomatic requiring management with drugs 
and electrophysiological procedures. Th e heart rate 
variability represents the measure of variation between 
two heart beats, that is being estimated by QRS complexes, 
ECG Holter evaluated in 24h by monitoring[1].
Th ere are two methods of heart rate variability analysis: 
time domain analysis and frequency domain analysis, 
with the same importance [1, 2]. 
Th e time domain analysis is determined by measuring two 
normal succesive QRS complexes and than calculating 
the average heart frequency, the diff erence between the 
shortest and the longest NN sequence, diff erence between 
night and day heart frequency.
Th e analysis frequency domain off ers information about 
distribution of frequency function power. Spectrum 
appreciation of RR variability sequence makes possible a 
qualitative evaluation of vagus impulse infl uence on heart 
rate, showing the activity of sympathetic nervous system 
[2]. Spectrum analysis allows us to evaluate the vegetative 
modulation of the heart beat. Th is can be achieved by a 
fast transform Fourier in order to separate RR sequence 
into frequence bands.
Aim of study: evaluation of selective beta-blocker 
(bisoprolol) on  parameters of heart rate variability in 
children with supraventricular arrhythmias.
Materials and methods: the research was done upon 50 
children, age between 7 and 18 years,  with the following 
complains: heart pain, palpitation, irregular heart 
beat, fatique, vegetative disturbances (sweating, cold 
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Th e criterias of treatment where the following: 
sympathic tonus and hypersympatic vegetative reactivity, 
supraventricular extrasistoly and ventricular on Holter 
ECG 24 h monitoring. Two research groups have been 
formed: I group of 30 children (average age 12,93±0,52 
years) that have been administrated bisoprolol in usual 
dosage of 1,25-2,5/mg/24 h and II reasearch group, (average 
age 13,55±0,60 year) that reaceived placebo. Th e patients 
have undergone a primary exam at 1 month and than 3 
months. Primary and secondary visit included anamnesis, 
standart clinical exam, ECG, ECOCG with colored Doppler, 
monitoring Holter ECG 24 h with heart rate variability 
evaluation and home automatic monitoring of BP in 24 h. 
Th e monitoring of patients during the stage of treatment 
included also the secondary eff ect evaluation. We can 
mention that aft er a month in a patient from the I reasearch 
group the treatment has been changed by including 
amiodaron (due to the fact of heart beat disturbances that 
have appeared and hemodinamic changes), one patient 
stoped receiving the treatment of an unknown reason and 
one patient didn’t come at the later visits.  In the I research 
group (children under bisoprolol) aft er a month 27 
children have been evaluated, aft er 3 months – 27 children.
ln the placebo group aft er a month 19 children have been 
evaluated (one of patients has been taken out due to the lack 
of compliance), aft er 3 months – 19 children. So that at the 
end 46 children have fi nished the research.
Th e patients from the research have been divided into 
three groups according to the age. Th is way, group I with 
children beween 7-10 years – 11 (22,0%),  II group  11-14 
years – 16 (32,0%) children and III  group patients in late 
pubertary stage 15-18 years – 23 (46,0%) [Figure 1].
Th e analysis of children in the research group according 
to age division determined the prevelage of 15-18 years 
children in 23 (46,0%) cases, and prevalege in the II 
group (placebo) of 12 (60,0%) children, with no evident 
age diff erence between the groups (p>0,05). Th e research 
group with arrhythmias included 30 boys (60,0%) and 20 
(40,0%) girls. Th e sex division revealed some pecularities 
(Figure 2).  
Fig. 1.  Group division according to age. 
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While analysing the gender of patients we may determine 
that there were more boys - 16 (53,3%) in the I research 
group (bisoprolol) and 14 (70,0%) in the II research 
group (placebo), with small statistic diff erences (p>0,05). 
From  the start all the children from the research groups 
with  arrythmias presented heart pains (children with 
sympathic tonus and hypersymphatic tonus) (90,0%) Th e 
pain was of a sharp feature, with the duration of 10-20 
minutes, while other factors were associated (emotion, 
physical eff ort, hyperventilation, pain without efort) in 
(80,0%). In   38,0% the pains were without iradiation. 
Also palpitations were present. So that we have 
detected palpitations in 88,0% case with a duration of 
20-30 minutes in 43,0% cases. Also we have noticed 
iregularities of heart beat mostly in the morning 37 
(74,0%) children. 
Th e heart rate variability (HRV), determines the 
variation between two heart beats. It has been revealed 
by analysis of sequent QRS complexes and also by 
analysing the time domain with statistic parameters 
appreciation: SDNN = average standart deviation 
of normal R-R sequences in 24 h and pNN50 = % of 
neighbour sequences R-R that diff er with more than  50 
ms, in 24 h. Th e initial parameters of HRV is shown in 
the Tabel 1.
Statistic parameters of time domain of HRV (SDNN și 
PNN 50) appreciated initially in two research groups 
didn’t diff er a lot (p>0,05).
Th e action of bisoprolol aft er one month and three 
months upon SDNN parameters, represents the world 
estimator of HRV shows a decrease that is more evident 
while comparing with the initial values of children from 
the II research group (-6,60; -4,89) vs children from the I 
research group (-1,48; -4,15), the diff erence between the 
initial level of SDNN in the research groups was quite 
discreet (p>0,05). 
Evaluation of statistic parameters in real time PNN50 in 
dynamics aft er a month and 3 months by treating with 
bisoprolol showed a growth while comparing with the 
initial results from the I group (6,42; 3,87) vs a decrease 
at patients from the II group (-0,40; -1,28) on placebo 
(p<0,01; p<0,05).   
Th is way according to the datas of time domain analysis 
we determined an increase of the statistic parameters in 
24 h. Aft er administarting bisoprolol in patients from 
the I research group PNN50, we were unable to detect 
decreased average level of statistic SDNN parameters 
comparing with the initial datas in the I research group. 
Long term therapy with bisoprolol showed good results 
upon the activities of the parasympathic vegetative 
nervous system and decreased activity of the symphatic 
system in patients with supraventricular arrythmias [3]. 
 We have completed the research by evaluating the 
heart beat rate through spectral analysis of vegetative 
modulation of heart beat by  Fourier  rapid changing of 
RR sequences in bands of high frequency (HF), low (LF), 
very low (VLF) and ratio LF/HF. 
Th e spectral analysis of HRV revealed a higher incidence 
of low frequency (LF) and very low frequency (VLF) 
bands in patients with arrythmias that explains the 
activity of the sympatic nevous system. 
Long term therapy with bisoprolol showed better results 
in a month of average values of low frequency bands (LF) 
and very low frequency bans (VLF) with an unsignifi cant 
decrease in patients of the I research group (-6502,33 ms) 
vs (-47,43 ms) from the  II research group also results of the 
I group (-66334,41 ms) vs (-2291,71 ms) II group (p>0,05). 
Evaluation of average values of spectral parameters 
(VLF) and (LF) in long term treatment with bisoprolol 
in 3 months showed an unsignifi cant decrease in I group 
patients (-43652,07; -6013,42 ms) vs patients from the 
II group (-3077,73; -71,33 ms) [p>0,05], revealing a 
decreased activity of the symphatic nervous system in I 
group patients. 
Ratio LF/HF considered as being a parameter of 
sympathic- vagal equilibrium, presented decreased 
average value aft er a month (-1,34±0,84) vs (-0,08±0,11) 
patients from the II group (p>0,05). Aft er 3 months was 
Tabel 1. Statistic parameters dynamics of heart rate variability while long time treatment with bisoprolol 
Parameters
I research group II research group
P
N M m N M m
SDNN,
 Ms
initially 30 156,1 6,98 20 182,75 11,6 >0,05
1 month 27 155,41 6,93 20 176,15 11,02 >0,05
3 month 27 152,74 6,71 19 178,84 11,68 >0,05
Δ i-1 27 -1,48 3,96 20 -6,60 5,36 >0,05
Δ i-3 27 -4,15 5,63 19 -4,89 5,48 >0,05
PNN50,
%
initially 30 20,32 2,33 20 27,01 3,0 >0,05
1 month 27 27,31 2,79 20 26,6 2,95 >0,05
3 month 27 24,76 2,48 19 26,14 2,98 >0,05
Δ i-1 27 6,42** 1,85 20 -0,40 0,67 <0,01
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established a decreased average value of LF/HF ratio in 
children from the  I group (-0,44±0,78) vs (-0,03±0,05) 
children from the II group that represents a balance 
between symphatic and parasymphatic system.
Th e datas of the spectral analysis allowed to establish an 
important decrease of average parameters in children 
with arrythmias aft er a month and three. Th e action 
of bisoprolol on HRV spectral parameters has been 
explained by blockage of the  β adrenergic receptors that 
block the action of the symphatic nervous system and 
activation of the parasymphatic system. 
Conclusions:
1. Th e research groups were formed from patients 
with supraventricular arrythmias with vegetative 
symphatic tonus and hypersymphatic reactivity with 
heart pains 90,0%, palpitations in 88,0% and irregular 
heart beats in 74,0% cases.
2. Th e analysis of statistic parameters of heart beat 
variability in long term treatment with bisoprolol 
showed a change in results in 1 and 3 months: 
decreased levels of SDNN (-6,60; -4,89) in the placebo 
group vs (-1,48; -4,15) patients on bisoprolol (p>0,05); 
increased PNN50 in the bisoprolol group (6,42; 3,87) 
vs a decreased value in the (-0,40; -1,28)  placebo 
group (p<0,01; p<0,05).
3. Spectral parameters appreciation of heart rate variability 
in a month and 3 months while bisoprolol treatment 
showed a decreased value of parameters LF (-6502,33 
ms; -6013,42  ms) vs (-47,43 ms; -71,33  ms) comparing 
with placebo group (p>0,05) and  parameters VLF levels 
in patients on bisoprolol (-66334,41  ms; -43652,57 
ms) vs (-2291,71  ms; -3077,53  ms) the placebo group 
(p>0,05).
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